What to Expect at This Year’s Asembia Specialty Pharmacy Summit
The COVID-19 pandemic has been an unrelenting trial—one that, in many ways, accelerated the pace of change in the life sciences industry. In the wake of breathtakingly fast novel vaccine development, an abrupt shift toward virtual care and a renewed focus on digital therapeutics, things look vastly different than they did less than two years […]
For Payers, Determining Aduhelm Coverage Is a Waiting Game
This article was originally published in FierceHealthcare. While it has been over a month since the FDA announced its controversial decision to approve Biogen’s Alzheimer’s drug, Aduhelm, payers have been slow to make any decisions—and for good reason. While the excitement around the approval is undeniable given the long-overdue unmet need for Alzheimer’s patients, there […]